Search

Your search keyword '"McGinnis, Lisa"' showing total 13 results
Start Over Author "McGinnis, Lisa" Publication Year Range Last 3 years
13 results on '"McGinnis, Lisa"'

1. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Author

Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., and Patil, Namrata S.

Published
2024
Full Text
View/download PDF

2. Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Author

Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., and Patil, Namrata S.

Published
2024
Full Text
View/download PDF

3. Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Author

Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., and Patil, Namrata S.

Published
2024
Full Text
View/download PDF

4. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

Author

Nabet, Barzin Y., Hamidi, Habib, Lee, Myung Chang, Banchereau, Romain, Morris, Stefanie, Adler, Leah, Gayevskiy, Velimir, Elhossiny, Ahmed M., Srivastava, Minu K., Patil, Namrata S., Smith, Kiandra A., Jesudason, Rajiv, Chan, Caleb, Chang, Patrick S., Fernandez, Matthew, Rost, Sandra, McGinnis, Lisa M., Koeppen, Hartmut, Gay, Carl M., Minna, John D., Heymach, John V., Chan, Joseph M., Rudin, Charles M., Byers, Lauren A., Liu, Stephen V., Reck, Martin, and Shames, David S.

Published
2024
Full Text
View/download PDF

5. Highly multiplexed, image-based pooled screens in primary cells and tissues with PerturbView

Author

Kudo, Takamasa, primary, Meireles, Ana M, additional, Moncada, Reuben, additional, Chen, Yushu, additional, Wu, Ping, additional, Gould, Joshua, additional, Hu, Xiaoyu, additional, Kornfeld, Opher, additional, Jesudason, Rajiv, additional, Foo, Conrad, additional, Hockendorf, Burkhard, additional, Bravo, Hector Corrada, additional, Town, Jason P, additional, Wei, Runmin, additional, Rios, Antonio, additional, Chandrasekar, Vineethkrishna, additional, Heinlein, Melanie, additional, Cai, Shuangyi, additional, Lu, Cherry Sakura, additional, Celen, Cemre, additional, Kljavin, Noelyn, additional, Jiang, Jian, additional, Hleap, Jose Sergio, additional, Kayagaki, Nobuhiko, additional, Melo, Felipe de Sousa e, additional, McGinnis, Lisa, additional, Li, Bo, additional, Singh, Avtar, additional, Garraway, Levi, additional, Rozenblatt-Rosen, Orit, additional, Regev, Aviv, additional, and Lubeck, Eric, additional

Published
2023
Full Text
View/download PDF

6. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Author

Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, and Abreu, Delvys Rodriguez

Abstract

Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone1. However, there remains little consensus on the mechanism(s) of response with this combination2. Here we find that a high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients treated with atezolizumab plus tiragolumab but not with atezolizumab alone. Serum sample analysis revealed that macrophage activation is associated with a clinical benefit in patients who received the combination treatment. In mouse tumour models, tiragolumab surrogate antibodies inflamed tumour-associated macrophages, monocytes and dendritic cells through Fcγ receptors (FcγR), in turn driving anti-tumour CD8+ T cells from an exhausted effector-like state to a more memory-like state. These results reveal a mechanism of action through which TIGIT checkpoint inhibitors can remodel immunosuppressive tumour microenvironments, and suggest that FcγR engagement is an important consideration in anti-TIGIT antibody development.A high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients with non-small cell lung cancer treated with atezolizumab plus tiragolumab, but not with atezolizumab alone. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. P1246: CELL TYPE IDENTIFICATION USING MULTIPLEX IMMUNOFLUORESCENCE (MIF) GUIDED MACHINE LEARNING IN DLBCL

Author

Chhor, Guillaume, primary, Vilchez, Samuel, additional, Chang, Patrick, additional, Novitskaya, Tatiana, additional, Hedvat, Cyrus, additional, Yu, Limin, additional, Resnick, Murray, additional, Franze, Kai, additional, Aguilar, Brizelle, additional, Barch, Mariya, additional, Jesudason, Raj, additional, Trotter, Ben, additional, Brosnan-Cashman, Jacqueline, additional, Liu, Yi, additional, Wapinski, Ilan, additional, Giltnane, Jennifer, additional, Hennek, Stephanie, additional, Zijlstra, Andries, additional, and Mcginnis, Lisa, additional

Published
2023
Full Text
View/download PDF

9. Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade

Author

Patil, Namrata S., primary, Srivats, Shyam, additional, Choi, Yoonha, additional, Guan, Xiangnan, additional, Nabet, Barzin, additional, McGinnis, Lisa, additional, Chiang, Eugene, additional, Dunkle, Alexis, additional, O’Gorman, Bill, additional, Chang, Patrick S., additional, Hu, Ruozhen, additional, Silva, John, additional, Han, Joy, additional, Au-Yeung, Amelia, additional, Takahashi, Chikara, additional, Molden, Nandini, additional, Daggumati, Pallavi, additional, Connolly, Wendy, additional, Johnson, Melissa, additional, Abreu, Delvys Rodriguez, additional, Cho, Byoung Chul, additional, Italiano, Antoine, additional, Gil-Bazo, Ignacio, additional, Felip, Enriqueta, additional, Mellman, Ira, additional, Meng, Raymond, additional, Mariathasan, Sanjeev, additional, Johnston, Robert, additional, and Shames, David S., additional

Published
2023
Full Text
View/download PDF

10. Abstract 5705: Digital pathology based prognostic & predictive biomarkers in metastatic non-small cell lung cancer

Author

Qamra, Aditi, primary, Srivastava, Minu K., additional, Fuentes, Eloisa, additional, Trotter, Ben, additional, Biju, Raymond, additional, Chhor, Guillaume, additional, Cowan, James, additional, Gendreau, Steven, additional, Lincoln, Webster, additional, McGinnis, Lisa, additional, Molinero, Luciana, additional, Patil, Namrata S., additional, Schedlbauer, Amber, additional, Schulze, Katja, additional, Stanford-Moore, Adam, additional, Chambre, Laura, additional, Wapinski, Ilan, additional, Shames, David S., additional, Koeppen, Hartmut, additional, Hennek, Stephanie, additional, Fridlyand, Jane, additional, Giltnane, Jennifer M., additional, and Amitai, Assaf, additional

Published
2023
Full Text
View/download PDF

11. 475 Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade

Author

Patil, Namrata, primary, Meng, Raymond, additional, Johnston, Robert, additional, Chang, Patrick, additional, Srivats, Shyam, additional, Choi, Yoonha, additional, Guan, Xiangnan, additional, Nabet, Barzin, additional, McGinnis, Lisa, additional, Chiang, Eugene, additional, Pham, Thinh, additional, Dunkle, Alexis, additional, O’Gorman, Bill, additional, Mellman, Ira, additional, Hu, Ruozhen, additional, Silva, John, additional, Han, Joy, additional, Au-Yeung, Amelia, additional, Takahashi, Chikara, additional, Molden, Nandini, additional, Daggumati, Pallavi, additional, Connolly, Wendy, additional, Johnson, Melissa, additional, Abreu, Delvys Rodriguez, additional, Cho, Byoung Chul, additional, Italiano, Antoine, additional, Bazo, Ignacio Gil, additional, Felip, Enriqueta, additional, Mariathasan, Sanjeev, additional, Bais, Carlos, additional, and Shames, David, additional

Published
2022
Full Text
View/download PDF

12. Multiplexed, image-based pooled screens in primary cells and tissues with PerturbView.

Author

Kudo T, Meireles AM, Moncada R, Chen Y, Wu P, Gould J, Hu X, Kornfeld O, Jesudason R, Foo C, Höckendorf B, Corrada Bravo H, Town JP, Wei R, Rios A, Chandrasekar V, Heinlein M, Chuong AS, Cai S, Lu CS, Coelho P, Mis M, Celen C, Kljavin N, Jiang J, Richmond D, Thakore P, Benito-Gutiérrez E, Geiger-Schuller K, Hleap JS, Kayagaki N, de Sousa E Melo F, McGinnis L, Li B, Singh A, Garraway L, Rozenblatt-Rosen O, Regev A, and Lubeck E

Abstract

Optical pooled screening (OPS) is a scalable method for linking image-based phenotypes with cellular perturbations. However, it has thus far been restricted to relatively low-plex phenotypic readouts in cancer cell lines in culture due to limitations associated with in situ sequencing of perturbation barcodes. Here, we develop PerturbView, an OPS technology that leverages in vitro transcription to amplify barcodes before in situ sequencing, enabling screens with highly multiplexed phenotypic readouts across diverse systems, including primary cells and tissues. We demonstrate PerturbView in induced pluripotent stem cell-derived neurons, primary immune cells and tumor tissue sections from animal models. In a screen of immune signaling pathways in primary bone marrow-derived macrophages, PerturbView uncovered both known and novel regulators of NF-κB signaling. Furthermore, we combine PerturbView with spatial transcriptomics in tissue sections from a mouse xenograft model, paving the way to in situ screens with rich optical and transcriptomic phenotypes. PerturbView broadens the scope of OPS to a wide range of models and applications., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results